Some chemokine can be used in anti-tumor immunotherapy by its chemotactic function on tumor cells.
部分趋化因子通过趋化和调节免疫效应细胞的功能来发挥抗肿瘤免疫作用。
DC vaccines are always made by been pulsed with tumor peptide or complex antigen in anti-tumor immunotherapy.
目前在抗肿瘤免疫治疗中，最常用的负载dc的方式有应用抗原肽和全抗原两种。
This research is going to studying the anti-tumor activity of tumor antigen induced cord blood cells based on the definition of adoptive immunotherapy.
本研究正是从过继性免疫细胞治疗的概念出发，探讨肿瘤抗原诱导的脐血细胞的抗肿瘤效应。
The development of technique to generate DCs has recently led to new approaches to cancer immunotherapy that will be the anti tumor mechanisms of this review.
DC在抗肿瘤免疫治疗策略中的变迁则源于对其抗肿瘤免疫机制的认识，就其近年的研究进展作一综述。
NK cells, as the effectors in antibody-dependent cell mediated cytotoxicity, play important roles in anti-tumor immune response. They now have become the hot point in the study on tumor immunotherapy.
NK细胞作为抗体依赖细胞毒作用的效应器，在抗肿瘤免疫中发挥着重要作用，成为目前肿瘤免疫治疗的研究热点。
CONCLUSION: CIK cells have strong proliferative ability and higher cytotoxicity to tumor cells in vitro, which could be used as a potential anti-tumor adoptive immunotherapy in clinic.
结论：CIK细胞在体外扩增能力强，对肿瘤细胞的杀伤活性高，有望成为新一代抗肿瘤过继免疫细胞制剂而应用于临床。
Conclusion: IL-18 in combination with IL-2 may increase the anti-tumor activity of NK92, which provides the experimental basis for immunotherapy of ovarian tumor with NK92 cells.
结论：IL - 18联合IL - 2可提高NK92细胞的抗肿瘤活性，为临床应用NK92细胞免疫治疗卵巢肿瘤提供了实验依据。
The cell used in adoptive immunotherapy must have strong cytotoxic and proliferative ability, so CIK cell is thought of the new generation anti-tumor adoptive immunity treatment.
用于过继免疫治疗的活性细胞必须具有较强的细胞活性和增殖力，CIK细胞被认为是新一代抗肿瘤过继细胞免疫治疗的首选方案。
The cell used in adoptive immunotherapy must have strong cytotoxic and proliferative ability, so CIK cell is thought of the new generation anti-tumor adoptive immunity treatment.
用于过继免疫治疗的活性细胞必须具有较强的细胞活性和增殖力，CIK细胞被认为是新一代抗肿瘤过继细胞免疫治疗的首选方案。
应用推荐